Literature DB >> 6399954

The effect of terodiline on patients with detrusor instability.

J R Macfarlane, D A Tolley.   

Abstract

In a double-blind cross-over study the effects and safety of terodiline were evaluated in 24 patients with detrusor instability. The optimum dosage was assessed by comparing 37.5 mg and 50 mg with placebo in three 4-week periods. All patients were assessed subjectively and by cystometry. Two-thirds of patients who completed the trial obtained symptomatic relief with terodiline although objectively there was only a weak dose-related tendency to favour terodiline. Ten patients reported side effects. Two patients did not complete the study due to drug intolerance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6399954

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  5 in total

1.  Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.

Authors:  B Hallén; A Magnusson; S Bogentoft; P Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Block and modified gating of cardiac calcium channel currents by terodiline.

Authors:  T Ogura; S Jones; L M Shuba; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 4.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

5.  Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.

Authors:  B Hallén; S Bogentoft; S Sandquist; S Strömberg; G Setterberg; E Ryd-Kjellén
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.